ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The FDA’s ODD program was developed to encourage research into therapies for rare diseases that specifically affect fewer than 200,000 people in the United States. The key benefits to the program include seven years of market exclusivity in the US, exemption from FDA user fees, up to 25 per cent in US clinical tax credits and an exemption from the Pediatric Research Equity Act. The company says the designation recognises the potential therapeutic relevance of efti in soft tissue sarcoma, supporting its glowing clinical data.

Immutep says that in 38 evaluable patients, the study met its primary endpoint, with 51.5 per cent showing no tumour growth. The results comfortably exceeded the pre-specified target of 35 per cent and stack up strongly against historical benchmarks of around 15 per cent from radiotherapy alone. The news couldn’t have come at a better time for the company.

Last month, the company shed nearly 90 per cent of its value, or half a billion dollars in market cap, on the terrible news from an independent commission that recommended discontinuing its TACTI-004 Phase III study on non-small cell lung cancer for its lead candidate, efti.